Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 2/20 | 0.64 |
| ▸ | USP30 | Q70CQ3 | 12/20 | 0.62 |
| ▸ | OTUD7B | Q6GQQ9 | 4/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19281680 | 1.00 | UCHL1 (0.64) | UCHL1USP30OTUD7BMKNK1KDR | |
| SCHEMBL19281709 | 1.00 | UCHL1 (0.64) | UCHL1USP30OTUD7BMKNK1KDR | |
| SCHEMBL19281711 | 1.00 | UCHL1 (0.64) | UCHL1USP30OTUD7BMKNK1KDR | |
| SCHEMBL17643843 | 0.85 | UCHL1 (0.66) | UCHL1USP30OTUD7BMKNK1KDR | |
| SCHEMBL19281675 | 0.85 | UCHL1 (0.66) | UCHL1USP30OTUD7BMKNK1KDR | |
| SCHEMBL17632529 | 0.85 | UCHL1 (0.66) | UCHL1USP30OTUD7BMKNK1KDR | |
| SCHEMBL17643764 | 0.83 | UCHL1 (0.63) | UCHL1USP30OTUD7BMKNK1KDR | |
| SCHEMBL19281693 | 0.83 | UCHL1 (0.63) | UCHL1USP30OTUD7BMKNK1KDR | |
| SCHEMBL17632430 | 0.83 | UCHL1 (0.63) | UCHL1USP30OTUD7BMKNK1KDR | |
| SCHEMBL19281647 | 0.81 | USP30 (0.63) | UCHL1USP30OTUD7BMKNK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197883-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2017-08-02 | — | — | EP | claimed |
| WO-2016046530-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2016-03-31 | — | — | WO | claimed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| EP-3197883-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046530-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247365-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | UCHL1 1/4885USP30 19/4885OTUD7B 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.